HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $56

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $48 to $56.